Annual Current Liabilities
$34.52 M
-$2.51 M-6.78%
December 31, 2023
Summary
- As of February 26, 2025, LYEL annual total current liabilities is $34.52 million, with the most recent change of -$2.51 million (-6.78%) on December 31, 2023.
- During the last 3 years, LYEL annual current liabilities has fallen by -$14.77 million (-29.96%).
- LYEL annual current liabilities is now -29.96% below its all-time high of $49.28 million, reached on December 31, 2020.
Performance
LYEL Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Current Liabilities
$33.51 M
+$2.63 M+8.53%
September 30, 2024
Summary
- As of February 26, 2025, LYEL quarterly total current liabilities is $33.51 million, with the most recent change of +$2.63 million (+8.53%) on September 30, 2024.
- Over the past year, LYEL quarterly current liabilities has dropped by -$1.01 million (-2.92%).
- LYEL quarterly current liabilities is now -47.36% below its all-time high of $63.66 million, reached on June 30, 2021.
Performance
LYEL Quarterly Current Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Current Liabilities Formula
Current Liabilities = Accounts Payable + Short-Term Debt + Accrued Expenses + Other Current Liabilities
LYEL Current Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -6.8% | -2.9% |
| 3 y3 years | -30.0% | -28.3% |
| 5 y5 years | +56.6% | -47.4% |
LYEL Current Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -26.1% | at low | -34.6% | +8.8% |
| 5 y | 5-year | -30.0% | +56.6% | -47.4% | +8.8% |
| alltime | all time | -30.0% | +56.6% | -47.4% | +8.8% |
Lyell Immunopharma Current Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $33.51 M(+8.5%) |
| Jun 2024 | - | $30.88 M(-4.6%) |
| Mar 2024 | - | $32.35 M(-6.3%) |
| Dec 2023 | $34.52 M(-6.8%) | $34.52 M(-1.6%) |
| Sep 2023 | - | $35.06 M(+2.0%) |
| Jun 2023 | - | $34.39 M(+11.7%) |
| Mar 2023 | - | $30.80 M(-16.8%) |
| Dec 2022 | $37.03 M | $37.03 M(-27.7%) |
| Sep 2022 | - | $51.22 M(+1.8%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2022 | - | $50.29 M(+22.5%) |
| Mar 2022 | - | $41.05 M(-12.2%) |
| Dec 2021 | $46.74 M(-5.2%) | $46.74 M(-21.2%) |
| Sep 2021 | - | $59.28 M(-6.9%) |
| Jun 2021 | - | $63.66 M(+12.1%) |
| Mar 2021 | - | $56.81 M(+15.3%) |
| Dec 2020 | $49.28 M(+123.6%) | - |
| Dec 2020 | - | $49.28 M |
| Dec 2019 | $22.05 M | - |
FAQ
- What is Lyell Immunopharma annual total current liabilities?
- What is the all time high annual current liabilities for Lyell Immunopharma?
- What is Lyell Immunopharma annual current liabilities year-on-year change?
- What is Lyell Immunopharma quarterly total current liabilities?
- What is the all time high quarterly current liabilities for Lyell Immunopharma?
- What is Lyell Immunopharma quarterly current liabilities year-on-year change?
What is Lyell Immunopharma annual total current liabilities?
The current annual current liabilities of LYEL is $34.52 M
What is the all time high annual current liabilities for Lyell Immunopharma?
Lyell Immunopharma all-time high annual total current liabilities is $49.28 M
What is Lyell Immunopharma annual current liabilities year-on-year change?
Over the past year, LYEL annual total current liabilities has changed by -$2.51 M (-6.78%)
What is Lyell Immunopharma quarterly total current liabilities?
The current quarterly current liabilities of LYEL is $33.51 M
What is the all time high quarterly current liabilities for Lyell Immunopharma?
Lyell Immunopharma all-time high quarterly total current liabilities is $63.66 M
What is Lyell Immunopharma quarterly current liabilities year-on-year change?
Over the past year, LYEL quarterly total current liabilities has changed by -$1.01 M (-2.92%)